Literature DB >> 24150267

The completeness of cancer treatment data on the National Health Collections.

Jason Gurney1, Diana Sarfati, Elizabeth Dennett, Jonathan Koea.   

Abstract

The New Zealand Ministry of Health (MoH) maintains a number of National Collections, which contain data on diagnoses, procedures and service provision for patients. There are concerns that these collections may underestimate the provision of cancer treatment, but the extent to which this is true is largely unknown. In this brief report, we focus on the Auckland region to illustrate the extent to which the National Collections undercount receipt of surgery in patients with breast, colon or renal cancer, and receipt of chemo- and/or radiotherapy for breast cancer patients with regional extent of disease (all diagnosed 2006-2008). We collected treatment data from the National collections and augmented this with data from Cancer Centres, breast cancer registers, private hospitals and personal clinician databases. The National Collections were used to determine 'baseline' treatment data, and we then compared receipt of treatment to that observed on the augmented dataset. We found that the National Collections undercounted receipt of surgery by 13-19%, and receipt of chemo- or radiotherapy for breast cancer patients by 18% and 16% respectively. Our observations clearly point toward (1) a non-reporting private hospital 'effect' on surgery data completeness; and (2) underreporting of adjuvant therapy to the MoH by service providers.

Entities:  

Mesh:

Year:  2013        PMID: 24150267

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  6 in total

1.  The impact of the COVID-19 pandemic on cancer diagnosis and service access in New Zealand-a country pursuing COVID-19 elimination.

Authors:  Jason K Gurney; Elinor Millar; Alex Dunn; Ruth Pirie; Michelle Mako; John Manderson; Claire Hardie; Chris G C A Jackson; Richard North; Myra Ruka; Nina Scott; Diana Sarfati
Journal:  Lancet Reg Health West Pac       Date:  2021-03-22

2.  Differences in Breast Cancer Survival between Public and Private Care in New Zealand: Which Factors Contribute?

Authors:  Sandar Tin Tin; J Mark Elwood; Ross Lawrenson; Ian Campbell; Vernon Harvey; Sanjeewa Seneviratne
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

3.  Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?

Authors:  Sandar Tin Tin; J Mark Elwood; Charis Brown; Diana Sarfati; Ian Campbell; Nina Scott; Reena Ramsaroop; Sanjeewa Seneviratne; Vernon Harvey; Ross Lawrenson
Journal:  BMC Cancer       Date:  2018-01-08       Impact factor: 4.430

4.  Use of Non-Cancer Medications in New Zealand Women at the Diagnosis of Primary Invasive Breast Cancer: Prevalence, Associated Factors and Effects on Survival.

Authors:  Phyu Sin Aye; Oliver W Scott; J Mark Elwood; Diana Sarfati; Ross Lawrenson; Ian D Campbell; Marion Kuper-Hommel; Sandar Tin Tin
Journal:  Int J Environ Res Public Health       Date:  2020-10-29       Impact factor: 3.390

5.  Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study.

Authors:  Oliver William Scott; Sandar Tin Tin; J Mark Elwood; Alana Cavadino; Laurel A Habel; Marion Kuper-Hommel; Ian Campbell; Ross Lawrenson
Journal:  Breast Cancer Res Treat       Date:  2022-03-14       Impact factor: 4.872

6.  Associated Factors and Survival Outcomes for Breast Conserving Surgery versus Mastectomy among New Zealand Women with Early-Stage Breast Cancer.

Authors:  Mohammad Shoaib Abrahimi; Mark Elwood; Ross Lawrenson; Ian Campbell; Sandar Tin Tin
Journal:  Int J Environ Res Public Health       Date:  2021-03-08       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.